Health ❯ Medicine ❯ Pharmaceuticals ❯ Drug Development

Clinical Trials

Sanofi Secures Global Rights to ADEL’s Alzheimer’s Antibody in Deal Worth Up to $1.04 Billion

Targeting acetylated tau, the candidate has entered an FDA-cleared first-in-human trial with Sanofi set to lead later development.

Novo Nordisk’s Oral Semaglutide Fails to Slow Alzheimer’s in Dual Phase 3 Trials

Novartis Ianalumab Meets Efficacy and Safety Goals in Phase 3 Sjögren’s Trials

AI-Designed Rentosertib Improves Lung Function in Phase IIa IPF Trial